(Q44028578)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

title

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Lars Rosengren

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Anders Svenningsson

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Jan Lycke

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

Martin Gunnarsson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Markus Axelsson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Peter Sundström

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Charlotte Dahle

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Magnus Vrethem

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Tomas Olsson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Fredrik Piehl

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Niklas Norgren

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

8 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

83-89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21280078%20AND%20SRC:MED&resulttype=core&format=json

Axonal transection in the lesions of multiple sclerosis

21 January 2020

cites work

1 reference

Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis

21 January 2018

1 reference

Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

21 January 2018

1 reference

Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability

21 January 2018

1 reference

Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis

21 January 2018

1 reference

Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.

21 January 2018

1 reference

Acute axonal damage predicts clinical outcome in patients with multiple sclerosis

21 January 2018

1 reference

Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.

21 January 2018

1 reference

Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations

21 January 2018

1 reference

Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability

21 January 2018

1 reference

Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study.

21 January 2018

1 reference

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.

21 January 2018

1 reference

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

21 January 2018

1 reference

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

21 January 2018

1 reference

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS.

21 January 2018

1 reference